{"id":7770,"date":"2018-10-15T18:01:26","date_gmt":"2018-10-15T22:01:26","guid":{"rendered":"http:\/\/localhost:10028\/uncategorized\/what-you-should-know-about-fourniers-gangrene\/"},"modified":"2022-08-18T21:16:13","modified_gmt":"2022-08-19T01:16:13","slug":"fourniers-kangreni-hakkinda-bilmeniz-gerekenler","status":"publish","type":"post","link":"https:\/\/napolilaw.lemonadestand.org\/tr\/article\/fourniers-kangreni-hakkinda-bilmeniz-gerekenler\/","title":{"rendered":"Fournier Kangreni Hakk\u0131nda Bilmeniz Gerekenler"},"content":{"rendered":"

ABD G\u0131da ve \u0130la\u00e7 \u0130daresi (FDA)<\/a> A\u011fustos 2018'in sonlar\u0131nda, diyabetik ila\u00e7lar ile Fournier kangreni ad\u0131 verilen nadir ancak ya\u015fam\u0131 tehdit eden bir hastal\u0131k aras\u0131ndaki ba\u011flant\u0131 hakk\u0131nda bir uyar\u0131 yay\u0131nlad\u0131. Uyar\u0131, baz\u0131 FDA onayl\u0131 inhibit\u00f6rlere (SGLT2) \u00f6zeldir ve bunlar\u0131n b\u00f6brekleri \u00f6nlemek<\/a> \u015fekerin kana yeniden emilmesini engelleyerek kan \u015fekerini d\u00fc\u015f\u00fcrmeye yard\u0131mc\u0131 olur ve yeti\u015fkinlerde kalp krizi ve fel\u00e7 riskini art\u0131r\u0131r. 2 tip diyabet<\/a>. These medications include, but are not limited to, Invokana, Jardiance, and other SGLT2 inhibitors produced and distributed by global pharmaceutical companies. The warning was issued as a result of 12 confirmed cases of Fournier\u2019s gangrene linked to taking SGLT2 inhibitors between March 2013 and May 2018. The FDA\u2019s warning states that while there are only 12 confirmed cases linked to SGLT2 inhibitors, to include seven men and five women, the estimated 1.7 million patients who were prescribed these inhibitors in 2017 may potentially be at risk. The pharmaceutical attorneys at Napoli Shkolnik , along with the FDA, urge any individuals who are or may be experiencing symptoms to seek medical attention immediately. For patients and health professionals who notice side effects from using SGLT2 inhibitors, the FDA requests that you report your symptoms to the FDA MedWatch<\/a> raporlama program\u0131 hemen.<\/p>\n

Today, the pharmaceutical lawyers at Napoli Shkolnik will share useful statistics and facts, and explain the risk factors and symptoms of Fournier\u2019s gangrene. Should you or a loved one fall under the common risk factors or display symptoms, contact a health professional immediately. Then, reach out to Napoli Shkolnik \u2019s dedicated ila\u00e7 davas\u0131<\/a> potansiyel talebinizi tart\u0131\u015fmak i\u00e7in ekip.<\/p>\n

Fournier Kangrenini Anlamak<\/h2>\n

bu Mayo Klini\u011fi<\/a> Kangreni tipik olarak ekstremiteleri etkileyen \u201ckan ak\u0131\u015f\u0131n\u0131n olmamas\u0131 veya ciddi bakteriyel enfeksiyon nedeniyle v\u00fccut dokusunun \u00f6l\u00fcm\u00fc\u201d olarak tan\u0131mlar. Fournier kangreni bir nekrotizan enfeksiyon<\/a> bu son derece nadirdir, ancak \u00e7o\u011fu zaman \u015fekli bozar ve hatta \u00f6l\u00fcmc\u00fcld\u00fcr. Bu ciddi bakteriyel enfeksiyon, genital organlar\u0131n yumu\u015fak dokular\u0131n\u0131 (kaslar, sinirler, kan damarlar\u0131 ve ya\u011f) \u00e7evreleyen derinin alt\u0131ndaki dokuyu etkiler; daha spesifik olarak, vulva ve skrotum aras\u0131ndaki perine. Fournier kangreni tipik olarak erkekleri etkilerken, kad\u0131nlarda ve \u00e7ocuklarda bilinen vakalar olmu\u015ftur.<\/p>\n

Yararl\u0131 \u0130statistikler ve Ger\u00e7ekler<\/h3>\n